New York, New York–(Newsfile Corp. – January 20, 2025) – FOR WHAT: Rosen Law Firm, an international investor rights law firm, reminds purchasers of BioAge Labs, Inc. (NASDAQ: BIOA) shares pursuant to and/or traceable to BioAge’s registration statement for the offering initial public offering carried out on September 26, 2024 (the “IPO”), of the important Deadline March 10, 2025 for principal applicant.
AND THEN: If you purchased BioAge stock, you may be entitled to compensation without payment of fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the BioAge class action, go to https://rosenlegal.com/submit-form/?case_id=33167 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the court no later than March 10, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY THE ROSEN LAW: We encourage investors to select qualified advisors with a proven track record in leadership roles. Often, companies issuing reviews do not have significant experience, resources, or peer recognition. Many of these firms do not actually defend securities class actions, but are simply intermediaries who refer clients or partner with law firms that actually litigate the cases. Be careful when choosing a lawyer. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. The Rosen Law Firm obtained the largest securities class action settlement against a Chinese company at the time. Rosen Law Firm Ranked #1 by ISS Securities Class Action (WA:) Services for the number of securities class action settlements in 2017. The firm has been ranked in the top 4 every year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone, the company secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of the Plaintiffs Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.
CASE DETAILS: According to the lawsuit, defendants touted its lead product candidate, azelaprag, as part of BioAge’s ongoing STRIDES clinical trial, with expectations of initial results in 2025. Defendants also mentioned its collaboration with Eli Lilly and Company (NYSE:) (“Lilly”) Chorus clinical development organization that would advise and assist on all aspects of the design and execution of the STRIDES trial. Defendants further discussed the possibility of a second Phase 2 clinical trial combining azelaprag and semaglutide to treat obesity in individuals aged 18 and older. Therefore, the IPO told the public that there were no safety concerns and that BioAge expected optimal results and to achieve its primary objectives from its STRIDES clinical trial.
Contrary to these representations, BioAge halted the ongoing Phase 2 STRIDES study of its investigational drug candidate, azelaprag, after several subjects showed elevated levels of liver enzymes, warning of potential organ damage. As a result, defendants discontinued the clinical trial and halted enrollment. Because Defendants failed to disclose the potential for hepatic transaminitis in any of their previous Phase 1 clinical trials and in various preclinical toxicity studies, Defendants’ statements in BioAge’s registration statement were false and/or materially misleading at the time of IPO. When the true details were leaked to the market, the lawsuit claims investors suffered damages.
To join the BioAge class action, go to https://rosenlegal.com/submit-form/?case_id=33167 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No classes have been certified. Until a class is certified, you are not represented by an attorney unless you retain one. You can choose the lawyer of your choice. You can also remain an absent member of the group and do nothing at this point. An investor’s ability to participate in any potential future recovery is not dependent on its status as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook (NASDAQ:) : https://www.facebook.com/rosenlawfirm/.
Lawyer advertising. Previous results do not guarantee a similar result.
——————————-
Contact details:
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/237731